253 related articles for article (PubMed ID: 17464245)
1. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
Fandy TE; Carraway H; Gore SD
Cancer J; 2007; 13(1):40-8. PubMed ID: 17464245
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of epigenetic therapy in cancer.
Hellebrekers DM; Griffioen AW; van Engeland M
Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
4. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths EA; Gore SD
Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
[TBL] [Abstract][Full Text] [Related]
5. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Gore SD
J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
7. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Murgo AJ
Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
9. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
10. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy--a new development in pharmacology.
Peedicayil J
Indian J Med Res; 2006 Jan; 123(1):17-24. PubMed ID: 16567863
[TBL] [Abstract][Full Text] [Related]
13. DNA methyltransferase inhibitors: an updated patent review (2012-2015).
Xu P; Hu G; Luo C; Liang Z
Expert Opin Ther Pat; 2016 Sep; 26(9):1017-30. PubMed ID: 27376512
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
16. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
San José-Enériz E; Agirre X; Rabal O; Vilas-Zornoza A; Sanchez-Arias JA; Miranda E; Ugarte A; Roa S; Paiva B; Estella-Hermoso de Mendoza A; Alvarez RM; Casares N; Segura V; Martín-Subero JI; Ogi FX; Soule P; Santiveri CM; Campos-Olivas R; Castellano G; de Barrena MGF; Rodriguez-Madoz JR; García-Barchino MJ; Lasarte JJ; Avila MA; Martinez-Climent JA; Oyarzabal J; Prosper F
Nat Commun; 2017 May; 8():15424. PubMed ID: 28548080
[TBL] [Abstract][Full Text] [Related]
17. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
19. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
[TBL] [Abstract][Full Text] [Related]
20. The application of delivery systems for DNA methyltransferase inhibitors.
Lim SP; Neilsen P; Kumar R; Abell A; Callen DF
BioDrugs; 2011 Aug; 25(4):227-42. PubMed ID: 21815698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]